Pacira BioSciences' Accounts Payables fell 8.67% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 8.67%. This contributed to the annual value of $19.1 million for FY2024, which is 21.88% up from last year.
Latest data reveals that Pacira BioSciences reported Accounts Payables of $17.7 million as of Q3 2025, which was down 41.29% from $30.1 million recorded in Q2 2025.
Over the past 5 years, Pacira BioSciences' Accounts Payables peaked at $30.1 million during Q2 2025, and registered a low of $7.9 million during Q3 2021.
Moreover, its 3-year median value for Accounts Payables was $18.7 million (2024), whereas its average is $19.2 million.
As far as peak fluctuations go, Pacira BioSciences' Accounts Payables crashed by 47.96% in 2024, and later soared by 157.98% in 2025.
Pacira BioSciences' Accounts Payables (Quarterly) stood at $10.5 million in 2021, then skyrocketed by 44.36% to $15.2 million in 2022, then climbed by 3.14% to $15.7 million in 2023, then climbed by 21.88% to $19.1 million in 2024, then dropped by 8.67% to $17.7 million in 2025.
Its last three reported values are $17.7 million in Q3 2025, $30.1 million for Q2 2025, and $23.2 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value